Statement: One patient in the primary trial had a 0.98 cm3 increase in Total MRI Functional Tumor Volume (FTV) over 3 months, almost 1cm3 less than average.
Primary_evidence: Outcome Measurement:    Mean Total MRI Functional Tumor Volume (FTV) Change From Baseline to Month 3 (V3)   Mean total MRI FTV change from baseline to month 3 (V3): For patients with more than one measureable lesion on the MRI, the sum over all measureable lesions on the MRI was calculated at each time point. V3 was calculated by subtracting the total MRI FTV measured (i.e. the sum over all lesions present with MRI FTV measurements) at 3 months from the total MRI FTV measured at baseline. For V3 the raw change in the volume will be calculated for each patient and a mean and 95% confidence interval will be constructed using two-sided t-tests.   Time frame: up to 3 months from start of treatment Results 1:    Arm/Group Title: Letrozole + MRI   Arm/Group Description: Protocol Therapy will consist of 6 months of letrozole, administered orally at a dose of 2.5 mg/day. Patients will have a bilateral MRI for disease evaluation at months 3 and 6.   Overall Number of Participants Analyzed: 68   Mean (95% Confidence Interval)   Unit of Measure: cubic centimeters  -1.93        (-2.87 to -0.98)